Luis Zeichner (Ostrosky-Zeichner) Ostrosky MD FACP, FIDSA, FSHEA, FECMM
Healthcare Associated Infections, Transplant/Immunocompromised States
Professor and chief, Memorial Hermann Endowed Chair, Division of Infectious Diseases, University of Texas Medical School at Houston
Join to view full profile
6431Fannin StMSB 2112.FHouston, TX 77030
Phone+1 713-500-6733
Fax+1 713-500-5495
Dr. Ostrosky is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Professor of medicine and epidemiology, Memorial Hermann Endowed Chair, Vice-Chair of Medicine, Director, Laboratory of Mycology Research, Division Chief, Infectious Diseases, UTHealth. Chief Epidemiology Officer, Memorial Hermann. Senior Editor, Journal of Antimicrobial Chemotherapy. Assoc. Editor, Clinical Infectious Diseases. Past-President of the Mycoses Study Group. Consultant, FDA and CDC.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Infectious Disease, 1999 - 2002
U Texas Med Sch1999 - 2002
Universidad Nacional Autonoma de MexicoClass of 1995, Honors
Certifications & Licensure
TX State Medical License 2002 - 2026
American Board of Medical QualityCMQ
Awards, Honors, & Recognition
- Fellow European Confederation of Medical Mycology
- Fellow American College of Physicians
- Fellow Infectious Diseases Society of America
Clinical Trials
- Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)
- Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Start of enrollment: 2017 Apr 01
- CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients Start of enrollment: 2020 Apr 17
Publications & Presentations
PubMed
- Molecular Evidence of Autochthonous Environmental Acquisition ofPediatric Infection in the United States.Maria G Segura, Brian Schwem, Rama Murthy Sakamuri, Carolyn Z Grimes, Maria Horne
Open Forum Infectious Diseases. 2026-09-01 - Bioarchaeological evidence of mycoses during the Late Antiquity-Early Middle Ages transition in Central Italy.Costantino Buzi, Antonio Merola, Daniela Messineo, Luis Ostrosky-Zeichner, Robert R Paine
Scientific Reports. 2026-09-01 - Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, ...Lindsey R Baden, Nirav S Shah, Sean T H Liu, Jonathan Cohen, James Moy
The Lancet. Infectious Diseases. 2026-08-31
Authored Content
- IDWeek 2018: Accuracy of the NHSN Central Line-Associated Bloodstream Infection DefinitionOctober 2018
- IDWeek 2018: Accuracy of the NHSN Central Line-Associated Bloodstream Infection DefinitionOctober 2018
- IDWeek 2018: Using Blockchain to Develop a Novel Propensity Score for Candidemia and Invasive CandidiasisOctober 2018
Press Mentions
Austin's Cyclospora Cases Remain in Normal Range as the Search for a Contamination Source ContinuesJuly 27th, 2026- Members of Congress Call for Mandatory Flu Vaccines for Military After Lackland Outbreak, Death ReportedJune 30th, 2026
- As Cases of a Rare, Deadly Infection Rise, Doctors Worry Fewer Teens Will Get VaccinatedJanuary 11th, 2026
Professional Memberships
- Fellow
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: